Introduction
Since the widespread availability of combination anti-retroviral therapy (cART), research has increasingly shown the benefit of early diagnosis and commencement of cART on the mortality and morbidity of patients living with HIV (PLHIV). 1, 2 However, in Australia in 2016, 33% of new HIV diagnoses are classified as late presenters (CD4þ count less than 350 cells/ml). 3 This proportion has remained unchanged over the last 10 years, despite changes in National testing policy. A high proportion of newly diagnosed PLHIV born overseas are late presenters, particularly people born in sub-Saharan Africa (43%) 3, 4 and SouthEast Asia (40%). 3 People reporting heterosexual sex as their risk exposure constitute a higher proportion of late presenters compared to those reporting male-to-male sex (43% vs. 29%). Amongst men reporting male-to-male sex as their risk exposure, age greater than 50 years, living in a regional area and injecting drug use as well as having sex with both men and women were factors associated with increased late diagnosis. 3 Late presentation is associated with higher healthcare costs, poor virological control and increased risk of transmission to others. [5] [6] [7] Thus, early diagnosis and treatment leads to a public health benefit via lower costs and a reduction in transmission of HIV, [5] [6] [7] as well as an individual benefit to the person diagnosed in terms of improved health outcomes via reductions in both AIDS-related and non-related diagnoses.
1,2
Differing approaches to HIV testing to allow earlier diagnosis have been suggested. Since 2006, the US Centres for Disease Control and Prevention has recommended universal testing for all adults and adolescents between 13 and 65 years old. 8 Tillison et al. found that diagnoses amongst patients reporting only heterosexual sex were 2.5 times more likely following routine HIV testing implementation in a primary care network in the U.S. 9 Phillips et al. showed routine implementation of HIV testing on an acute medical ward rather than risk based testing resulted in patients being diagnosed with higher CD4 counts in the U.K.
10
Since 2008, the European AIDS Clinical Society (EACS) and British HIV Association has recommended HIV indicator condition-based testing based on three groups of indicator conditions: opportunistic infections, conditions where HIV prevalence is greater than 0.1% and conditions where non-diagnosis of HIV would adversely affect management Supplementary  Table SA. 11-13 HIV-indicator condition-based testing does not require the clinician to detect or the patient to disclose riskfactors. The HIV Indicator Diseases across Europe studies (HIDES) demonstrated HIV prevalence was greater than 0.1% in conditions such as sexually transmitted infections, malignant lymphoma, cervical/anal dysplasia, herpes zoster, viral hepatitis, mononucleosis-like illness, leucopoenia or thrombocytopenia and seborrhoeic dermatitis. In the HIDES I study, 20% of patients diagnosed with HIV had a potentially HIV-related presentation in prior years, 23% with more than one presentation.
14 Studies suggest testing in conditions where HIV prevalence > 0.1% is cost-effective. 15, 16 In Australia, national surveillance for newly acquired HIV infection was established in 1991 and HIV tests became a Medicare-rebatable item in 2006. 17 Although HIV testing has traditionally been recommended in at risk groups, the National HIV testing policy has recommended HIV testing in relevant clinical conditions since 2011, 18 in line with the EACS guidelines. The aim of the current study was to evaluate prevalence of HIV indicator conditions in late-presenters with HIV infection and examine the demographics and co-diagnosis of opportunistic infection in this population.
Materials and methods
This was a retrospective cohort study taken at Monash Health, Victoria's largest healthcare network. The network provides care to a population of approximately 1.3 million people in SE Melbourne and adjacent areas. We identified all patients older than 18 years of age with HIV infection managed at Monash Health between 2000 and 2014. Patients aged less than 18 years were excluded as established HIV indicator conditions differ for paediatrics populations. Data was collected from the hospital medical record and HIV database [including age, sex, country of birth, mode of HIV infection acquisition, opportunistic infection(s) at time of diagnosis] and our laboratory information system (including full blood examination, CD4 count at diagnosis and hepatitis serology).
Patients with late presentation of HIV infection (CD4 < 350 cells/ml) were identified and a detailed retrospective chart review was performed. The medical record was assessed for any EACS listed indicator condition 11 (Supplementary Table SA) .
Prevalence by type of indicator condition, number of indicator conditions, time between indicator conditions to HIV diagnosis and by year of diagnosis was calculated. Prevalence was calculated for fourteen HIV indicator conditions: unexplained loss of weight (greater than 10% for at least 30 days), herpes zoster, thrombocytopenia or leukopenia, candidiasis, community acquired pneumonia, viral hepatitis, unexplained fever (>3 weeks) or night sweats, diarrhoea, lymphadenopathy (>4 weeks), mononucleosis like illness, sexually transmitted infection, psoriasis or seborrhoeic dermatitis, peripheral neuropathy and cervical dysplasia. We compared the patients with late presentation of HIV infection (CD4 < 350 cells/ml) to the rest of the HIV positive cohort. Descriptive statistics were applied and comparisons were made using chi-squared tests.
This study was approved by Monash Health Research and Ethics.
Results
Four hundred and thirty-six patients with HIV infection were identified in our cohort. There were 82 late presenting patients diagnosed with CD4 count <350 cells/ml (Table 1) . Compared to the rest of the HIV cohort, there was a male preponderance (83% vs. 75%; P ¼ 0.11), late presenting patients were older (mean age 45 years compared to 39 years), more commonly born overseas (61% vs. 58%, P ¼ 0.68) and reported heterosexual transmission as their exposure risk (51% vs. 31%, P < 0.001). The average CD4 count for late presenters at diagnosis was 58 cells/ml for inpatients and 212 cells/ml for outpatients. Fifty percentage of the late presenting cohort presented with an opportunistic infection. Nine late presenters (14.75%) died in the first 12 months after diagnosis.
In terms of EACS HIV indicator conditions (Table 2 ), 6.3% of the late presenting cohort had previous opportunistic infection, 52.5% had a condition where prevalence of HIV was greater than 0.1% and 2.5% had a condition where HIV non-diagnosis would significantly impact on management. Fifty-five percent had at least one, 36.3% had at least two, 15.0% had at least three and 6.3% had four or more HIV indicator conditions. The time between diagnosis of HIV indicator condition and HIV diagnosis was at least 3 months in 41.3% and at least 12 months in 25%, with a median time of 12 months (IQR ¼ 4-24) (Figure 1 The most common HIV indicator conditions ( Table 3 ) that late-presenters newly diagnosed with HIV had were unexplained loss of weight (31.3%), herpes zoster (10%) thrombocytopenia/leukopenia (10%), candidiasis (oral or oesophageal) 10% and community acquired pneumonia 8.8%. Mononucleosis-like illness (3.8%), sexually transmitted infection (3.8%), seborrhoeic dermatitis (2.5%) and cervical dysplasia (1.3%) were uncommon presentations prior to HIV diagnosis.
Of patients with late presentation of HIV infection, 7/76 tested had serological evidence of past (1%) or current (7.5%) hepatitis C infection and 22/77 (28.5%) had past (22.5%) or current (5%) Hepatitis B infection. Three patients had hepatitis B infection and four patients had hepatitis C diagnosed prior to HIV infection.
Discussion
This study found that male gender, older age, being born overseas and heterosexual risk factor for HIV acquisition were factors associated with late presentation with HIV. Similar risk factors have been identified in overseas cohorts. 19 However, there have been no specific testing strategies targeted at these groups, who may be missed by traditional risk-based testing.
Furthermore, patients with a new diagnosis of HIV present for multiple health conditions related to HIV in the years preceding diagnosis; this finding is consistent with the literature. A retrospective US cohort study of 125 HIV positive patients found these patients had made 649 previous health care visits where no HIV test was performed. The majority of visits (33.6%) occurred in the primary health care setting, followed by emergency care (28.2%) and specialist clinics (19.0%). 20 Similarly, Ellis et al., 2010 found in an audit of centres providing adult HIV services, 25% of patients had a missed opportunity for diagnosis with the most common indicator conditions for weight loss, sexually transmitted infection, blood dyscrasia or lymphadenopathy. 21 Reasons explaining the high prevalence of HIV indicator conditions in late-presenting patients with new HIV diagnosis include (i) Australian guidelines previously favouring a riskbased HIV testing strategy, (ii) lack of knowledge of HIV indicator conditions amongst physicians, (iii) lack of recommendation for HIV testing in indicator condition specific guidelines and (iv) lack of physician time, skills or motivation in different clinical settings.
Whilst the low prevalence of previous opportunistic infections as an indicator condition suggests that there is widespread knowledge of AIDS defining conditions, there may be lack of widespread knowledge of other HIV indicator conditions and consensus that they warrant HIV testing. There is often heterogeneity amongst specialists regarding HIV testing. A recent national cross-sectional cohort study reported that that a large percentage of physicians (48%) commencing anti-viral therapy for hepatitis B reported not always testing for HIV, with 30% only testing when risk factors were present. 22 This may be exacerbated by an absent recommendation for HIV testing for patients with HIV indicator conditions in non-HIV specialty guidelines despite national and international testing guidelines. Lord et al., 2016 found the majority of UK non-HIV speciality guidelines did not recommend HIV testing in HIV indicator conditions. 23 No similar data is available on recommendation for HIV testing in indicator conditions in Australian non-HIV specialty guidelines. By analysing the adequacy of existing guidelines in line with HIV testing policy, steps can be taken to engage guideline development groups and non-HIV physicians to improve the rate of HIV testing. This study was limited by data that was contained in the medical record of a public healthcare network. These records incorporated a wide range of sources including specialty clinics, inpatient admissions, primary care referral or self-report. However, it likely to be an underestimate of prior HIV indicator conditions, as we were unable to review records of other hospitals, community-based specialists and in particular primary care, where the majority of indicator conditions will be diagnosed.
There are many barriers regarding HIV testing for non-HIV specialists, which include time, the perception of required skills and clinician motivation. As demonstrated in the HIDES 2 study, these clinician factors result in a variable rate (31-99%) of HIV test offer by clinicians, despite a high uptake when offered to patients (>95%), creating an unhelpful high barrier to HIV testing. 24, 25 It is hoped that by educating physicians regarding the use of HIV-indicator based testing, particularly by targeting medical guidelines, stigma will be decreased, HIV testing will be normalized and this will in turn enable early diagnosis and treatment for PLHIV.
Conclusion
We found that overall 55% of late presenting patients with HIV had presented with at least one indicator condition prior to HIV diagnosis. The most common indicator condition was unexplained loss of weight, followed by herpes zoster and leukopenia or thrombocytopenia. There was no decrease in the prevalence of late presenting patients with HIV indicator conditions over time. We theorize that this may be due to a combination of slow dissemination of knowledge regarding recommended HIV testing policy and HIV indicator conditions and perceived lack of skills and time by non-HIV physicians. Future focus would be to partner with non-HIV specialist guideline development groups to improve education and training for non-HIV physicians, who will have the majority of early interactions with patients with HIV prior to diagnosis.
